TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $3.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 410.64% from the company’s current price.
TransCode Therapeutics Trading Down 9.6 %
Shares of NASDAQ:RNAZ opened at $0.59 on Thursday. The stock has a 50 day moving average of $0.44 and a 200 day moving average of $0.70. TransCode Therapeutics has a 12-month low of $0.22 and a 12-month high of $19.42.
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). As a group, research analysts expect that TransCode Therapeutics will post -2.06 earnings per share for the current year.
Institutional Investors Weigh In On TransCode Therapeutics
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
See Also
- Five stocks we like better than TransCode Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Texas Roadhouse Stock Steering for New Highs This Year
- The 3 Best Blue-Chip Stocks to Buy Now
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What Do S&P 500 Stocks Tell Investors About the Market?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.